CN106498090A - A kind of test kit for detecting DNA mismatch repair system and application thereof - Google Patents
A kind of test kit for detecting DNA mismatch repair system and application thereof Download PDFInfo
- Publication number
- CN106498090A CN106498090A CN201710030484.8A CN201710030484A CN106498090A CN 106498090 A CN106498090 A CN 106498090A CN 201710030484 A CN201710030484 A CN 201710030484A CN 106498090 A CN106498090 A CN 106498090A
- Authority
- CN
- China
- Prior art keywords
- bat
- dna
- test kit
- repair system
- mismatch repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a kind of test kit for detecting DNA mismatch repair system and application thereof, the test kit includes an amplification system, and the amplification system includes PCR primer mixed liquor and PCR reactant liquors；Described PCR primer mixed liquor includes microsatellite locus.The microsatellite locus of the test kit of the present invention have higher sensitivity and accuracy, go for detecting different cancers, including colorectal carcinoma, carcinoma of endometrium, gastric cancer, cancer of pancreas, pulmonary carcinoma and breast carcinoma.The present invention's is more preferable containing the repeatability for detecting the test kit of the microsatellite locus of DNA mismatch repair system, can detect multiple microsatellite locus simultaneously, improve detection efficiency.
Description
Technical field
The invention belongs to DNA mismatch repair system field, and in particular to a kind of examination for detecting DNA mismatch repair system
Agent box and application thereof.
Background technology
Human genome contains short series connection repetitive dna sequence, also referred to as microsatellite sequence (microsatellite), these
Easily there is copy error due to its repetitive nature in sequence, under normal circumstances, these mistakes can pass through the mispairing reparation of DNA
(MMR) carrying out reparation correction, the MMR systemic-functions defect of DNA can cause microsatellite instability to system
(microsatellite instability, MSI), MSI are marks of Jessica Lynch's syndrome (Lynch syndrome),
There is generation in 90% Jessica Lynch's syndrome.
Microsatellite instability shows as same microsatellite locus between Different Individual and same individual normal structure
Between some abnormal structures, the number of the recurring units of microsatellite locus is different.Numerous studies in recent years show：MSI with
There is closely related, such as colorectal cancer, gastric cancer, carcinoma of endometrium etc. in tumor, MSI is the biomarker that cancer occurs.Beautiful
National Cancer association of state advises that the colorectal cancer patients of the right side of fifty should do MMR detections, and some medical centers are to institute abroad
Some colorectal tumor tissues carry out the detection of MMR protein immunizations groupization or MSI detections, to determine which patient needs to carry out
Lynch syndromes related gene is detected.
According to document report, in about 15% colorectal cancer, there is MSI phenomenons, compared with the colorectal cancer without MSI, take
Colorectal cancer its prognosis with MSI preferably, there is abundant evidence that MMR protein expressions disappearance or MSI-H are the second stage of knots
One mark of rectal cancer prognosis bona, and there is MSI and both patients drug reaction without MSI is also different.Additionally,
For whether the second stage of colorectal cancer needs adjuvant chemotherapy, clinically consider a important information is exactly microsatellite instability.
Therefore, MSI is detected to the significant of colorectal cancer patients.In 2011, with regard to the U.S. of colorectal cancer examination
In national synthesis cancer net guide (NCCN Guidelines), MSI has become primary detection project, it is recommended that 5 detection sites
For the confirmation of MSI stability, two and two or more site change as MSI-H, and a site changes as MSI-
L, changes as MSI-S without site.
Research shows that it is pre- that second phase/tri- phase colorectal cancer patients find that MSI-L or MSS can improve really by adjuvant chemotherapy
Afterwards, but MSI-H but can not significantly benefit from 5-fluorouracil (5-FU) adjuvant chemotherapy, survival rate is low all the better within 5 years.Colon
Rectal cancer is common malignant gastrointestinal tumors, and China has ten thousand people of 13-16 to suffer from colorectal cancer every year, and wherein sickness rate accounts for tumor and sends out
The 3rd of sick rate.There is the Sporadic Colorectal Carcinoma of MSI, with different clinical pathologies, molecular biological characteristics, performance
For：Age of onset is little；There is drug resistance to some chemotherapeutics such as 5-FU, cisplatin etc., MSI-H is the second stage of colon cancer prognosis bona
One mark, and the outcome prediction index that patient can not benefit from fluorouracil list medicine adjuvant chemotherapy.
Additionally, detection MSI can also aid in PD-1 antibody medications.Report in the ASCO of 2015, colon cancer MMR gene table
Can be used as the outcome prediction index of PD-1 Antybody therapies up to situation.Reported according to conference clinical data, MMR expresses defect
(dMMR) effective percentage of patient PD-1 treatments reaches 62%, and it is most top that related experimental result will be published in the whole world in the end of the year 2015
On medical journal NEJM, the sensation of medical circle is caused.Prediction precision of the situation of MMR genes to PD-1 colorectal cancer curative effects
General outcome prediction index B7-H1 (PD-L1) before being significantly larger than.
In USA and EU, MSI detections are included conventional sense by NCCN, but apply the doctor of MSI detections in China
Institute is also considerably less, and for the most frequently used still enteroscopy of colorectal cancer examination, feces occult blood is detected, clysis with barium detection etc..
It is used for both at home and abroad at present detecting that the method for MSI mainly has：(1) ImmunohistochemistryMethods Methods (IHC), predominantly detects MLH1,
MSH2, MSH6, PMS2, this method can not detect the biologic activity of MMR albumen, it is possible to false positive results are produced,
And IHC experimental results are affected by the level of skill of antibody sources and operator, this can cause result between Different hospital
Diversity, causes to diagnose inaccurate even medical tangle；(2) direct sequencing, to each region direct Sequencing of MMR genes, this
Time-consuming for the method for kind, and price is costly.
Content of the invention
It is an object of the invention to provide a kind of test kit for detecting DNA mismatch repair system and application thereof, the reagent
The microsatellite locus of box can be used in detecting cancer DNA mismatch repair system, its remolding sensitivity ImmunohistochemistryMethods Methods (IHC) method
Higher, the test kit repeatability of the present invention more preferably can detect multiple MSI sites simultaneously, improve detection efficiency.
In order to achieve the above object, the invention provides a kind of test kit for detecting DNA mismatch repair system, the examination
Agent box includes an amplification system, and the amplification system includes PCR primer mixed liquor and PCR reactant liquors；Described PCR primer mixed liquor
Comprising microsatellite locus, the microsatellite locus include：NR-21、NR-24、BAT-25、BAT-26、MONO-27、BAT-48、BAT-
49a、BAT-49b、BAT-50a、BAT-50b、BAT-51a、BAT-51b、BAT-51c、BAT-51d、BAT-51e、BAT-51f、
BAT-52a、BAT-52b、BAT-53a、BAT-53b、BAT-53c、BAT-54、BAT-55、BAT-56a、BAT-56b、BAT-57、
BAT-59、BAT-59b、BAT-60a、BAT-60b、BAT-60c、BAT-62、BAT-63a、BAT-63b、BAT-68a、BAT-
68b、BAT-69、BAT-72、BAT-73、BAT-79、BAT-83、BAT-90、BGT-60、Penta C、Penta D、Penta E
In any one or two or more tandem sequence repeats site mononucleotide A or G repeat more than 40.
Shown in described microsatellite locus table specific as follows：(Accession Number are that the gene of Genebank is logged in
Number)
；Upper table nucleotide repeats how many nucleotide for repeating represented；Series connection of the microsatellite locus for 1-6 base
Repetitive sequence, these sites are mononucleotide A or G tandem sequence repeats site, or five nucleotide tandem sequence repeats sites, (A)
In 21, A represents Adenosine acid, and numeral 21 is represented and repeats 21 A.
Described PCR primer mixed liquor includes nucleotide sequence SEQ ID NO：Any one or two kinds in 1-92 with
On.
Described nucleotide sequence SEQ ID NO：5 ' the end fluorescent labels of 1-92, the fluorescent marker bag
Containing FL (Fluorescein), JOE (6-carboxy-4 ', 5 '-dichloro-2 ', 7 '-dimethoxyfluorescein),
TMR(carboxy-tetramethylrhodamine)、ROX(Carboxyl-X-Rhodamine)、ET-CXR(Energy
Transfer-carboxy-X-rhodamine)、ET-TMR(Energy Transfer-carboxy-
Tetramethylrhodamine) or in FAM (Fluorescein amidite) any one or two or more.
Described amplification system also includes DNA profiling, and the volume ratio of the component of the amplification system is PCR reactant liquors：PCR draws
Thing mixed liquor：DNA profiling：Water=1～2：1～2：1～4：2～7.
Described PCR reactant liquors include：10-100mM Tris-HCl, 10-250mM KCl, 1-10mM MgCl2, 0.1-
10mM dNTP, 0.1-10U/ μ L Taq archaeal dna polymerases.
The detection method determines the presence of microsatellite locus mutation using fluorescent labeling high performance capillary electrophoresis.
Described mutation includes：Insertion mutation or deletion mutation.
Present invention also offers the purposes for detecting the test kit of DNA mismatch repair system described in a kind of basis, institute
The microsatellite locus that states can be used in detecting that DNA mismatch repair system, the DNA mismatch repair system are included in cancerous tissue
DNA mismatch repair system.
Described cancer includes：Colorectal carcinoma, carcinoma of endometrium, gastric cancer, cancer of pancreas, in pulmonary carcinoma, and breast carcinoma
Any one.
Described microsatellite locus are used for the unstability of the microsatellite for detecting cancer, enable the test kit as detection cancer
The test kit of disease DNA mismatch repair system.
Provided by the present invention for detecting test kit of DNA mismatch repair system and application thereof, with advantages below：
1st, using the microsatellite locus detection of the present invention, its remolding sensitivity IHC methods are higher.
2nd, long tandem sequence repeats site of the invention has higher sensitivity and accuracy.
3rd, test kit of the invention distinguishes different microsatellite positions using fluorescent labeling and capillary electrophoresis clip size
Point, it is achieved that detect multiple MSI sites simultaneously in a PCR system, improve detection efficiency.
4th, the DNA that test kit of the invention detection can be extracted from same section be repeated several times experiment, and traditional exempt from
The same section of epidemic disease groupization cannot be done and repeat to test, than traditional method with more repeatability, and the test experience knot of the present invention
Fruit adopts software analysis, reduces know clearly artificial subjective judgment and standardization.
5th, do not have internal reference in the microsatellite detection system that US National cancer research institute proposes, the present invention is used
Used as internal reference, it is to use in this area first to be in Penta sites, and which can carry out interior control to whole detection system.
6th, detection of the invention makes result more accurately, intuitively using capillary electrophoresis detection method.
7th, the present invention adopts data analysis software, result is preferably illustrated.
8th, the present invention selects different microsatellite locus to go for detecting different cancers, including colorectal carcinoma,
Carcinoma of endometrium, gastric cancer, cancer of pancreas, pulmonary carcinoma and breast carcinoma.
Description of the drawings
Fig. 1 is the DNA typing collection of illustrative plates in the short mononucleotide tandem sequence repeats site of experimental example of the present invention 2.
Fig. 2 is the short mononucleotide tandem sequence repeats site of the normal structure of experimental example of the present invention 2 and colorectal carcinoma tissues
Contrast DNA typing collection of illustrative plates.
Fig. 3 is the DNA typing collection of illustrative plates in the long mononucleotide tandem sequence repeats site of experimental example of the present invention 2.
Specific embodiment
Technical scheme is described further below in conjunction with drawings and Examples.
Using the test kit of the present invention 2 colorectal cancer patients are detected to be embodied as situation specific as follows：
Experimental example 1PCR amplified reactions
1st, PCR reaction systems
Table 1：React concrete component
DNTP in above-mentioned table 1 includes dATP, dGTP, dTTP and dCTP, and the use of dATP, dGTP, dTTP and dCTP is dense
Spend for 1mM.
The mixture of the primer pair for using refers to selects microsatellite locus and its forward primer comprising the present invention and downstream to draw
The mixture of thing, final concentration of 0.1-1 μM of each primer pair (forward primer and downstream primer).As shown in table 2, it is two mixing
The concrete component of thing.
Table 2：The concrete component of two mixed liquors
In above-mentioned table 2,5 ' end fluorescent marker JOE be 6-carboxy-4 ', 5 '-dichloro-2 ', 7 '-
Dimethoxyfluorescein, FL are Fluorescein, and ET-TMR is Energy Transfer-carboxy-
Tetramethylrhodamine, "/" represent that, without fluorescent labeling, 5 ' ends are hydroxyl.Wherein, microsatellite locus Penta C and
Penta D are used as internal reference.
2nd, experiment condition
ABI veriti PCR instruments selected by PCR instrument device
Table 3：The actual conditions of PCR reactions
2 μ L PCR reactant liquors and 2 μ L PCR primers mixed liquors are mixed, 1-2 μ L DNA profilings is added, and is added water 4-6 μ
L to PCR reaction systems cumulative volume is 10 μ L.Enter performing PCR reaction with reference to the concrete reaction condition of above-mentioned table 3.
2 Capillary Electrophoresis Experiment of experimental example
The PCR primer for having expanded is taken, internal standard (Promega companies, endogenous control ILS500) and Methanamide is added, at 95 DEG C
Lower dry bath 3min, ice-water bath 3min.ABI 3500Dx instrument loadings, open 3500Dx data collection softwares, and model on editor is led
Enter fragment analysis program, click on operation.Comprise the following steps that：
(1) prepare loading sample：1 μ L of gained PCR primer, add 10 μ L of Methanamide, DNA molecular standard internal standard ILS500 1
μL；
(2) capillary electrophoresis：Capillary electrophoresis program setting is carried out according to ABI3500Dx instruments operation instructions, specifically
As follows：
A, preparation instrument；B, heating furnace for preheating are to 60 DEG C；C, preparation sample Sptting plate are simultaneously loaded onto instrument；D, inspection apparatus
State；E, establishment import a Sptting plate；F, distribution Sptting plate content；G, Ligature plate；H, loading Sptting plate are to transport
OK, sample introduction list is created；I, bring into operation.
After fragment analysis operation is finished, by initial data, the file of the entitled .fsa of suffix imports data analysis software
GeneMapper4.0, is analyzed to fluorescence signal, imports Panel and Bin, clicks on Analyze, and analysis is finished and obtains capillary
Electrophoresis tube collection of illustrative plates and associated clip size information.
Experimental result：
As shown in figure 1, using microsatellite locus being：NR-21、NR-24、BAT-25、BAT-26、Mono-27、Penta C
Microsatellite locus detection is carried out to the tumor tissues of colorectal cancer patients 1 and normal structure with the test kit of Penta D, every
Find have the clip size in a site different from normal structure in cancerous tissue or polyp tissue, then illustrate that the site is
Microsatellite instability, as shown in Fig. 2 compared with 5 microsatellite locus of colorectal carcinoma tissues and normal structure, its nucleotide fragments
Size have different degrees of reduction, such as BAT-26 sites to reduce 10bp, NR-21 sites reduce 6bp, and BAT-25 sites subtract
Little 7bp, Mono-27 sites reduce 6bp, and NR-24 sites reduce 5bp, show that colorectal carcinoma tissues are equal in 5 sites
There are MSI phenomenons, illustrate that the specimens are MSI-H.
As shown in figure 3, using microsatellite locus being：BAT-52a、BAT-55、BAT-56a、BAT-57、BAT-59、Penta
The test kit of C and Penta D carries out microsatellite locus detection to the tumor tissues of colorectal cancer patients 2 and normal structure, all
It is to find have the clip size in a site different from normal structure in cancerous tissue or polyp tissue, then the site is described
For microsatellite instability.As a result show that the size of the nucleotide fragments of the microsatellite locus of cancerous tissue has different degrees of subtracting
Little, such as BAT-59 sites reduce 13bp, and BAT-52 sites reduce 23bp, and BAT-56 sites reduce 10bp, BAT-55 positions
Point reduces 5bp, and BAT-57 sites reduce 11bp, show that colorectal carcinoma tissues MSI phenomenons occur in above-mentioned site, say
The bright specimens are MSI-H.
In sum, test kit for detecting DNA mismatch repair system of the invention and application thereof, the test kit includes
Microsatellite locus, the microsatellite locus can be used in detecting cancer DNA mismatch repair system, its remolding sensitivity ImmunohistochemistryMethods Methods
(IHC) method is higher, and test kit repeatability more preferably, can detect multiple MSI sites simultaneously, improve detection efficiency, but also
Oncotherapy prognosis can be judged and instruct the medication of 5-fluorouracil (5-FU) and programmed death receptor -1 (PD-1) antibody.
Although present disclosure has been made to be discussed in detail by above preferred embodiment, but it should be appreciated that above-mentioned
Description is not considered as limitation of the present invention.After those skilled in the art have read the above, for the present invention's
Multiple modifications and substitutions all will be apparent.Therefore, protection scope of the present invention should be limited to the appended claims.
<110>Puluomaige Biological Products Co., Ltd., Shanghai
<120>A kind of test kit for detecting DNA mismatch repair system and application thereof
<130> 0
<160> 92
<170> PatentIn version 3.5
<210> 1
<211> 24
<212> DNA
<213>Synthetic
<400> 1
cggagtcgct ggcacagttc tatt 24
<210> 2
<211> 25
<212> DNA
<213>Synthetic
<400> 2
tcgcgtttac aaacaagaaa agtgt 25
<210> 3
<211> 20
<212> DNA
<213>Synthetic
<400> 3
ccattgctga attttacctc 20
<210> 4
<211> 20
<212> DNA
<213>Synthetic
<400> 4
attgtgccat tgcattccaa 20
<210> 5
<211> 20
<212> DNA
<213>Synthetic
<400> 5
tcgcctccaa gaatgtaagt 20
<210> 6
<211> 24
<212> DNA
<213>Synthetic
<400> 6
atttctgcat tttaactatg gctc 24
<210> 7
<211> 24
<212> DNA
<213>Synthetic
<400> 7
tgactacttt tgacttcagc cagt 24
<210> 8
<211> 24
<212> DNA
<213>Synthetic
<400> 8
aaccattcaa catttttaac cctt 24
<210> 9
<211> 24
<212> DNA
<213>Synthetic
<400> 9
tgtgaaccac ctatgaattg caga 24
<210> 10
<211> 26
<212> DNA
<213>Synthetic
<400> 10
attgcttgca gtgagcagag atcgtt 26
<210> 11
<211> 24
<212> DNA
<213>Synthetic
<400> 11
tataattagg tcccagatca ctta 24
<210> 12
<211> 24
<212> DNA
<213>Synthetic
<400> 12
ggcaatgttt aaagacatgg atac 24
<210> 13
<211> 24
<212> DNA
<213>Synthetic
<400> 13
aaacacagtg agactcccta tcta 24
<210> 14
<211> 24
<212> DNA
<213>Synthetic
<400> 14
acaggacaga gatggcacgg acag 24
<210> 15
<211> 24
<212> DNA
<213>Synthetic
<400> 15
ctgctgttgc atcgcggccc aatg 24
<210> 16
<211> 24
<212> DNA
<213>Synthetic
<400> 16
aagaagcccc tctcctccgg tctc 24
<210> 17
<211> 24
<212> DNA
<213>Synthetic
<400> 17
aggcatgggc aaggacttga tgtc 24
<210> 18
<211> 24
<212> DNA
<213>Synthetic
<400> 18
ctggatgtta gccgtttgtc agag 24
<210> 19
<211> 24
<212> DNA
<213>Synthetic
<400> 19
ggtttgcttg aggccagaac ttca 24
<210> 20
<211> 24
<212> DNA
<213>Synthetic
<400> 20
ctcatagcag ccttaaatta ctga 24
<210> 21
<211> 24
<212> DNA
<213>Synthetic
<400> 21
agcctgggcg acagagcaag actc 24
<210> 22
<211> 24
<212> DNA
<213>Synthetic
<400> 22
caagggcagc atcattatga caac 24
<210> 23
<211> 28
<212> DNA
<213>Synthetic
<400> 23
tgtgtgcaaa ttgtgaggga ggtaggta 28
<210> 24
<211> 24
<212> DNA
<213>Synthetic
<400> 24
agcggggtgc ggtggctcat atct 24
<210> 25
<211> 24
<212> DNA
<213>Synthetic
<400> 25
ctgaggcagg agaatggaga gtag 24
<210> 26
<211> 24
<212> DNA
<213>Synthetic
<400> 26
ctctgctacc cgggttcaaa cagt 24
<210> 27
<211> 28
<212> DNA
<213>Synthetic
<400> 27
gaggctgagg caggagaatg gcgtgaac 28
<210> 28
<211> 28
<212> DNA
<213>Synthetic
<400> 28
cgctgacgca gaacctgaaa ttgtgatt 28
<210> 29
<211> 24
<212> DNA
<213>Synthetic
<400> 29
aggttgcagt gagccaggat cata 24
<210> 30
<211> 24
<212> DNA
<213>Synthetic
<400> 30
atcacatcat ctgtcccacc taac 24
<210> 31
<211> 24
<212> DNA
<213>Synthetic
<400> 31
tgggcgacag agcgagactc cgtc 24
<210> 32
<211> 24
<212> DNA
<213>Synthetic
<400> 32
cagcggccca taaattctat gtta 24
<210> 33
<211> 28
<212> DNA
<213>Synthetic
<400> 33
ctaacttccc agcaacttcc tttacact 28
<210> 34
<211> 24
<212> DNA
<213>Synthetic
<400> 34
attgggcaga cactgaacta gctt 24
<210> 35
<211> 28
<212> DNA
<213>Synthetic
<400> 35
gggagaacct tgctgtcttt cagataat 28
<210> 36
<211> 24
<212> DNA
<213>Synthetic
<400> 36
agggctcctg gaatatggtt gtac 24
<210> 37
<211> 28
<212> DNA
<213>Synthetic
<400> 37
aacctccacc ttcccagctc aagtgaca 28
<210> 38
<211> 23
<212> DNA
<213>Synthetic
<400> 38
ggcgacagcg agactccgtc tca 23
<210> 39
<211> 24
<212> DNA
<213>Synthetic
<400> 39
ctgaggcagg agaatggcgt gaac 24
<210> 40
<211> 28
<212> DNA
<213>Synthetic
<400> 40
atgatgctgg cctcataaaa agagttag 28
<210> 41
<211> 26
<212> DNA
<213>Synthetic
<400> 41
tatcctagct tggcctgttt aagacc 26
<210> 42
<211> 22
<212> DNA
<213>Synthetic
<400> 42
tgaggcagga gaatggcgtg aa 22
<210> 43
<211> 26
<212> DNA
<213>Synthetic
<400> 43
tttaatatac ctgctgatca atgata 26
<210> 44
<211> 21
<212> DNA
<213>Synthetic
<400> 44
gacacatggg atcatagcaa a 21
<210> 45
<211> 24
<212> DNA
<213>Synthetic
<400> 45
ttgggcgaca gagcaagacg actc 24
<210> 46
<211> 26
<212> DNA
<213>Synthetic
<400> 46
atttggtcag tgggggctct gttaag 26
<210> 47
<211> 26
<212> DNA
<213>Synthetic
<400> 47
tcagcagctg aaagaaatct gagtac 26
<210> 48
<211> 22
<212> DNA
<213>Synthetic
<400> 48
gcgataccca aagtcaatag tc 22
<210> 49
<211> 24
<212> DNA
<213>Synthetic
<400> 49
gaagctgcag taagccgaga ttgt 24
<210> 50
<211> 24
<212> DNA
<213>Synthetic
<400> 50
gccctcttaa ctcccatgac attc 24
<210> 51
<211> 22
<212> DNA
<213>Synthetic
<400> 51
agcctgggcg acagagcgag tc 22
<210> 52
<211> 23
<212> DNA
<213>Synthetic
<400> 52
ctcggggctc gggagatgag tga 23
<210> 53
<211> 28
<212> DNA
<213>Synthetic
<400> 53
cagcctaggt aacagagcaa gacctttg 28
<210> 54
<211> 23
<212> DNA
<213>Synthetic
<400> 54
gtttgcgtga tttgcgtgga ctt 23
<210> 55
<211> 23
<212> DNA
<213>Synthetic
<400> 55
ctcctgcctc atcctcccga gta 23
<210> 56
<211> 24
<212> DNA
<213>Synthetic
<400> 56
ccgagatcac gccactgcac tcta 24
<210> 57
<211> 28
<212> DNA
<213>Synthetic
<400> 57
tctcatttga gtggtggaag tgactggt 28
<210> 58
<211> 23
<212> DNA
<213>Synthetic
<400> 58
tattctttcg ggatgtaatc tct 23
<210> 59
<211> 26
<212> DNA
<213>Synthetic
<400> 59
cccgtctcta ctaaaaatac taaaac 26
<210> 60
<211> 28
<212> DNA
<213>Synthetic
<400> 60
aaaccaacaa taaggcaacc tcttagtc 28
<210> 61
<211> 28
<212> DNA
<213>Synthetic
<400> 61
tgccagagta gggtggtcca tggtactt 28
<210> 62
<211> 25
<212> DNA
<213>Synthetic
<400> 62
gcccaaaatg tgtttagtta gcttc 25
<210> 63
<211> 28
<212> DNA
<213>Synthetic
<400> 63
aggctgaagc aggagaatca cttaaaac 28
<210> 64
<211> 25
<212> DNA
<213>Synthetic
<400> 64
gccaagtgtc gcttgtaatt ctatt 25
<210> 65
<211> 26
<212> DNA
<213>Synthetic
<400> 65
gaatcttgtt tcggcctttg acctta 26
<210> 66
<211> 25
<212> DNA
<213>Synthetic
<400> 66
cgagatcacg ccaccgcact ctagc 25
<210> 67
<211> 27
<212> DNA
<213>Synthetic
<400> 67
aaatctaccc agctctgtaa cgagaga 27
<210> 68
<211> 28
<212> DNA
<213>Synthetic
<400> 68
aagctctgtt tggcaagtgt taattgta 28
<210> 69
<211> 28
<212> DNA
<213>Synthetic
<400> 69
ttggaatgta ttctctgggt ttggcagt 28
<210> 70
<211> 27
<212> DNA
<213>Synthetic
<400> 70
ttcaggaggc tgaggtggga ggattgt 27
<210> 71
<211> 22
<212> DNA
<213>Synthetic
<400> 71
acctaggcaa taccatctaa ga 22
<210> 72
<211> 24
<212> DNA
<213>Synthetic
<400> 72
gttgcctgtt cactctgata gtct 24
<210> 73
<211> 23
<212> DNA
<213>Synthetic
<400> 73
agcctgggtg acagagcgag act 23
<210> 74
<211> 28
<212> DNA
<213>Synthetic
<400> 74
ttagagttat ttgttgggat gagaatct 28
<210> 75
<211> 22
<212> DNA
<213>Synthetic
<400> 75
ctgggcgaca gagcgagact cc 22
<210> 76
<211> 26
<212> DNA
<213>Synthetic
<400> 76
tctcctgcct tagcctcccg agtagc 26
<210> 77
<211> 27
<212> DNA
<213>Synthetic
<400> 77
tcctctccct aaaaagctcc ccctaag 27
<210> 78
<211> 28
<212> DNA
<213>Synthetic
<400> 78
aggtcaaggc tgcggtaagc tgtgatcg 28
<210> 79
<211> 28
<212> DNA
<213>Synthetic
<400> 79
tccccacttt gtcctgcaca ctcctacc 28
<210> 80
<211> 23
<212> DNA
<213>Synthetic
<400> 80
gggcgacaga gcgagactcc gtc 23
<210> 81
<211> 28
<212> DNA
<213>Synthetic
<400> 81
aagatttaat agacatgcgc agaacact 28
<210> 82
<211> 23
<212> DNA
<213>Synthetic
<400> 82
ccagcctggg caaaagagca agt 23
<210> 83
<211> 28
<212> DNA
<213>Synthetic
<400> 83
acaaacatga aaaggcaaat gatagaac 28
<210> 84
<211> 27
<212> DNA
<213>Synthetic
<400> 84
agaggttgca gtgagccaag attgtag 27
<210> 85
<211> 23
<212> DNA
<213>Synthetic
<400> 85
gagggatgaa gggggacaga tag 23
<210> 86
<211> 23
<212> DNA
<213>Synthetic
<400> 86
cattctcact ccacgccctc tat 23
<210> 87
<211> 24
<212> DNA
<213>Synthetic
<400> 87
catggcattg gggacatgaa caca 24
<210> 88
<211> 24
<212> DNA
<213>Synthetic
<400> 88
cactgagcgc ttctagggac ttct 24
<210> 89
<211> 24
<212> DNA
<213>Synthetic
<400> 89
cagcctaggt gacagagcaa gaca 24
<210> 90
<211> 24
<212> DNA
<213>Synthetic
<400> 90
atttgcctaa cctatggtca taac 24
<210> 91
<211> 33
<212> DNA
<213>Synthetic
<400> 91
tgggttatta attgagaaaa ctccttacaa ttt 33
<210> 92
<211> 26
<212> DNA
<213>Synthetic
<400> 92
attaccaaca tgaaagggta ccaata 26
Claims (10)
1. a kind of test kit for detecting DNA mismatch repair system, it is characterised in that the test kit includes an amplification system,
The amplification system includes PCR primer mixed liquor and PCR reactant liquors；Described PCR primer mixed liquor includes microsatellite locus, and this is micro-
Satellite site includes：NR-21、NR-24、BAT-25、BAT-26、MONO-27、BAT-48、BAT-49a、BAT-49b、BAT-
50a、BAT-50b、BAT-51a、BAT-51b、BAT-51c、BAT-51d、BAT-51e、BAT-51f、BAT-52a、BAT-52b、
BAT-53a、BAT-53b、BAT-53c、BAT-54、BAT-55、BAT-56a、BAT-56b、BAT-57、BAT-59、BAT-59b、
BAT-60a、BAT-60b、BAT-60c、BAT-62、BAT-63a、BAT-63b、BAT-68a、BAT-68b、BAT-69、BAT-72、
Any one in BAT-73, BAT-79, BAT-83, BAT-90, BGT-60, Penta C, Penta D, Penta E or two kinds
Above tandem sequence repeats site mononucleotide A or G repeat more than 40；
Shown in described microsatellite locus table specific as follows：
2. the test kit for detecting DNA mismatch repair system according to claim 1, it is characterised in that described PCR
Primer mixed liquor includes nucleotide sequence SEQ ID NO：In 1-92 any one or two or more.
3. the test kit for detecting DNA mismatch repair system according to claim 1, it is characterised in that described core
Nucleotide sequence SEQ ID NO：5 ' the end fluorescent labels of 1-92, the fluorescent marker comprising FL, JOE, TMR,
In ROX, ET-CXR, ET-TMR or FAM any one or two or more.
4. the test kit for detecting DNA mismatch repair system according to claim 1, it is characterised in that described expansion
Increasing system also includes DNA profiling, and the volume ratio of the component of the amplification system is PCR reactant liquors：PCR primer mixed liquor：DNA moulds
Plate：Water=1～2：1～2：1～4：2～7.
5. the test kit for detecting DNA mismatch repair system according to claim 1, it is characterised in that described PCR
Reactant liquor includes：10-100mM Tris-HCl, 10-250mM KCl, 1-10mM MgCl2, 0.1-10mM dNTP, 0.1-10U/
μ L Taq archaeal dna polymerases.
6. a kind of inspection for detecting the test kit of DNA mismatch repair system according to any one in claim 1-5
Survey method, it is characterised in that the detection method determines the presence of microsatellite locus mutation using fluorescent labeling high performance capillary electrophoresis.
7. the detection method for detecting the test kit of DNA mismatch repair system according to claim 6, its feature exist
In described mutation includes：Insertion mutation or deletion mutation.
8. a kind of use for detecting the test kit of DNA mismatch repair system according to any one in claim 1-5
On the way, it is characterised in that described microsatellite locus can be used in detecting DNA mismatch repair system, the DNA mismatch repair system bag
Include the DNA mismatch repair system in cancerous tissue.
9. the purposes for detecting the test kit of DNA mismatch repair system according to claim 8, it is characterised in that institute
The cancer that states includes：Colorectal carcinoma, carcinoma of endometrium, gastric cancer, cancer of pancreas, any one in pulmonary carcinoma, and breast carcinoma.
10. the purposes for detecting the test kit of DNA mismatch repair system according to claim 8, it is characterised in that institute
The microsatellite locus that states are used for the unstability of the microsatellite for detecting cancer, enable the test kit as detection cancer DNA mismatch
The test kit of repair system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710030484.8A CN106498090A (en) | 2017-01-16 | 2017-01-16 | A kind of test kit for detecting DNA mismatch repair system and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710030484.8A CN106498090A (en) | 2017-01-16 | 2017-01-16 | A kind of test kit for detecting DNA mismatch repair system and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106498090A true CN106498090A (en) | 2017-03-15 |
Family
ID=58345250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710030484.8A Pending CN106498090A (en) | 2017-01-16 | 2017-01-16 | A kind of test kit for detecting DNA mismatch repair system and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106498090A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058551A (en) * | 2017-05-04 | 2017-08-18 | 北京诺禾致源科技股份有限公司 | Detect the instable method and device of microsatellite locus |
| CN107267505A (en) * | 2017-07-21 | 2017-10-20 | 首都医科大学 | Microsatellite marker and its application in the prognosis judgement of colorectal cancer and/or chemosensitivity prediction |
| CN107488739A (en) * | 2017-10-17 | 2017-12-19 | 生工生物工程（上海）股份有限公司 | A kind of Nucleic acid combinations, kit and the method for microsatellite instability detection |
| CN107502668A (en) * | 2017-09-23 | 2017-12-22 | 上海五色石医学研究股份有限公司 | The detection method of people's Y chromosome label site sY1291 a kind of and its application |
| CN108220405A (en) * | 2018-02-06 | 2018-06-29 | 上海汇真生物科技有限公司 | The method and kit of microsatellite stability state-detection |
| CN108315426A (en) * | 2018-04-12 | 2018-07-24 | 北京信诺佰世医学检验所有限公司 | Marker combination, primer sets and the kit of microsatellite sequence Detection of Stability |
| CN108676888A (en) * | 2018-07-12 | 2018-10-19 | 吉林大学 | A kind of pulmonary malignant tumour neurological susceptibility prediction kit and system |
| CN108676890A (en) * | 2018-07-12 | 2018-10-19 | 吉林大学 | A kind of female mammary gland malignant tumour neurological susceptibility prediction kit and system |
| CN108753965A (en) * | 2018-06-07 | 2018-11-06 | 凯杰（苏州）转化医学研究有限公司 | A kind of compound amplification detection system of microsatellite instability state and its application |
-
2017
- 2017-01-16 CN CN201710030484.8A patent/CN106498090A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| JEFFERY W. BACHER ET AL: "Development of a fluorescent multiplex assay for detection of MSI-High tumors", 《DISEASE MARKERS》 * |
| KATHLEEN M. MURPHY ET AL: "Comparison of the Microsatellite Instability Analysis System and the Bethesda Panel for the Determination of Microsatellite Instability in Colorectal Cancers", 《JOURNAL OF MOLECULAR DIAGNOSTICS》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058551A (en) * | 2017-05-04 | 2017-08-18 | 北京诺禾致源科技股份有限公司 | Detect the instable method and device of microsatellite locus |
| CN107058551B (en) * | 2017-05-04 | 2020-03-31 | 北京诺禾致源科技股份有限公司 | Method and device for detecting instability of microsatellite locus |
| CN107267505A (en) * | 2017-07-21 | 2017-10-20 | 首都医科大学 | Microsatellite marker and its application in the prognosis judgement of colorectal cancer and/or chemosensitivity prediction |
| CN107267505B (en) * | 2017-07-21 | 2020-10-30 | 首都医科大学 | Microsatellite markers and application thereof in prognosis determination and/or chemotherapy sensitivity prediction of colorectal cancer |
| CN107502668A (en) * | 2017-09-23 | 2017-12-22 | 上海五色石医学研究股份有限公司 | The detection method of people's Y chromosome label site sY1291 a kind of and its application |
| CN107488739A (en) * | 2017-10-17 | 2017-12-19 | 生工生物工程（上海）股份有限公司 | A kind of Nucleic acid combinations, kit and the method for microsatellite instability detection |
| CN108220405A (en) * | 2018-02-06 | 2018-06-29 | 上海汇真生物科技有限公司 | The method and kit of microsatellite stability state-detection |
| CN108315426A (en) * | 2018-04-12 | 2018-07-24 | 北京信诺佰世医学检验所有限公司 | Marker combination, primer sets and the kit of microsatellite sequence Detection of Stability |
| CN108753965A (en) * | 2018-06-07 | 2018-11-06 | 凯杰（苏州）转化医学研究有限公司 | A kind of compound amplification detection system of microsatellite instability state and its application |
| CN108753965B (en) * | 2018-06-07 | 2022-06-17 | 迈杰转化医学研究(苏州)有限公司 | Composite amplification detection system for microsatellite unstable state and application thereof |
| CN108676888A (en) * | 2018-07-12 | 2018-10-19 | 吉林大学 | A kind of pulmonary malignant tumour neurological susceptibility prediction kit and system |
| CN108676890A (en) * | 2018-07-12 | 2018-10-19 | 吉林大学 | A kind of female mammary gland malignant tumour neurological susceptibility prediction kit and system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106498090A (en) | A kind of test kit for detecting DNA mismatch repair system and application thereof | |
| CN106520931B (en) | EGFR genetic mutation detection primer probe and its kit | |
| CN112094915B (en) | Sarcoma fusion gene and/or mutation joint detection primer group and kit | |
| CN106834479A (en) | Microsatellite instability state analysis system in immunotherapy of tumors | |
| US11136628B2 (en) | Biomarkers useful for detection of types, grades and stages of human breast cancer | |
| CN108866192A (en) | Tumor marker STAMP-EP1 based on methylation modification | |
| CN110396517A (en) | It is a kind of that type oligonucleotide probe and its application being quenched for expanding the non-of anomaly target fragment | |
| JP6606554B2 (en) | Use of the methylated site of the Y chromosome as a diagnostic marker for prostate cancer | |
| CN108085395A (en) | Primer sets, kit and the method for cervical carcinoma polygenes DNA methylation assay based on high-flux sequence | |
| CN114107513B (en) | Detection method and kit for bladder urothelial cancer diagnosis | |
| CN105671187B (en) | Group of genes for molecular typing of head and neck squamous cell carcinoma and application thereof | |
| CN113355415B (en) | Detection reagent and kit for diagnosis or auxiliary diagnosis of esophageal cancer | |
| CN112094916B (en) | Plasma free DNA lung cancer gene joint detection kit | |
| CN108866191A (en) | Tumor marker STAMP-EP2 based on methylation modification | |
| CN106498035A (en) | A kind of construction method and its application for detecting chemotherapeutics gene SNP variation library for high-flux sequence | |
| CN112646888B (en) | Kit for detecting mammary tumor specific methylation | |
| CN109456968A (en) | Tumor marker STAMP-EP5 based on methylation modification | |
| CN106498036A (en) | A kind of construction method in the Drug Discovery SNP variations library for high-flux sequence detection and its application | |
| CN109554476A (en) | Tumor marker STAMP-EP3 based on methylation modification | |
| CN110541033A (en) | composition for detecting EGFR gene mutation and detection method | |
| JP6395131B2 (en) | Method for acquiring information on lung cancer, and marker and kit for acquiring information on lung cancer | |
| CN109652541A (en) | Tumor marker STAMP-EP6 based on methylation modification | |
| CN116970705A (en) | Nucleic acid product for methylation detection of urothelial oncogene, kit and application | |
| CN108456721A (en) | Synchronous detection gene mutation and the method and its application to methylate | |
| CN107641649B (en) | Primer pair, kit and method for detecting stability of NR27 locus of microsatellite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |